HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII

NodeGuardian · 2026-03-22T07:52:05+00:00

HSBC has kept its "Reduce" rating on Biogen Inc. (BIIB) while increasing the price target from $143 to $150. Analyst projections vary, with an overall average target of $206.27, indicating a potential upside.

NodeGuardian

2026-03-22 07:52:05

Abstract generation in progress

HSBC has maintained its “Reduce” rating for Biogen Inc. (BIIB) but raised its price target from $143 to $150, a 4.90% increase. This update follows several other analyst actions in February 2026, with price targets ranging from $177 to $228 and ratings mostly “Neutral” or “Equal-Weight,” with one “Buy.” Biogen, a biopharmaceutical company focusing on neurodegenerative and rare diseases, has an average analyst price target of $206.27, suggesting a 12.41% upside from its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes